PopPKPKPDMIPD/TDM

Secukinumab exposure and PASI dynamics

A subcutaneous PK/PD model linking secukinumab absorption and distribution to IL-17A pathway inhibition, delayed PASI response, and tolerance dynamics.

Explore and simulate

Therapeutic: Secukinumab
Target: IL17A, IL-17A
Disease: Psoriasis

Biological model

A subcutaneous PK/PD model linking secukinumab absorption and distribution to IL-17A pathway inhibition, delayed PASI response, and tolerance dynamics.

Intervention

Secukinumab

Biological focus

IL17A, IL-17A

Context

Psoriasis

Model details

A subcutaneous PK/PD model linking secukinumab absorption and distribution to IL-17A pathway inhibition, delayed PASI response, and tolerance dynamics.

Modeled states

AUC conc daymg*day/L

Modeled dynamic state for auc conc day.
A central mgmg

Modeled dynamic state for a central mg.
A depot mgmg

Modeled dynamic state for a depot mg.
A peripheral mgmg

Modeled dynamic state for a peripheral mg.
elapsed time dayday

Modeled dynamic state for elapsed time day.
pasidimensionless

Modeled dynamic state for pasi.
pre pasi1dimensionless

Modeled dynamic state for pre pasi1.
pre pasi2dimensionless

Modeled dynamic state for pre pasi2.
pre pasi3dimensionless

Modeled dynamic state for pre pasi3.
pre pasi4dimensionless

Modeled dynamic state for pre pasi4.
tol1dimensionless

Modeled dynamic state for tol1.
tol2dimensionless

Modeled dynamic state for tol2.

Key readouts

Central secukinumab concentrationunknown

Model-derived readout for central secukinumab concentration.
PASI scoredimensionless

Model-derived readout for pasi score.
IL-17A pathway drug effectunknown

Model-derived readout for il-17a pathway drug effect.
Tolerance driveunknown

Model-derived readout for tolerance drive.
Cumulative concentration exposuremg*day/L

Model-derived readout for cumulative concentration exposure.

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Starting configuration

Subject 1 300 mg every 4 weeks 20-cycle

How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance? Explore this intervention regimen through Central secukinumab concentration, PASI score, IL-17A pathway drug effect, Tolerance drive, Cumulative concentration exposure. This is a mechanistic product exploration, not a paper-result reproduction.

Questions to explore

How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance?

Starting result

This result reflects the starting settings. Run your changes to update it.

This scenario result is temporarily unavailable.

Model inputs

Five scientist-facing controls at most.

CL L day Model parameter controlling cl l day. L/dayV2 L Model parameter controlling v2 l. Lka 1 day Model parameter controlling ka 1 day. 1/dayic50 mg l Model parameter controlling ic50 mg l. mg/Limax Model parameter controlling imax. dimensionless

Compare a parameter

How does one model input change the response?

How do secukinumab regimen and individual PK/PD parameters shape PASI response and tolerance?

Parameter to compare

CL L day

Model parameter controlling cl l day.

Exploratory range around the default value.

Low High Points

5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.

Interpret with care

Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.

Review the server-confirmed fixed price before starting the comparison.

Comparative response

End-of-window response across the selected parameter values.

Choose an exploratory range around the default, review the fixed price, and run the comparison.

Scientific reference

Supporting publication

Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing

Pharmaceutics